LeonaBio, Inc.
Close on Oct 19, 2026
- Market cap
- $119.82M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | During market hours | – | $-0.80 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | – | $-1.68 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | – | $0.18 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | During market hours | – | $-0.23 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | During market hours | – | $-0.70 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | During market hours | – | $-0.69 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | During market hours | – | – | – |
Press releases
Announcements LeonaBio filed with the SEC
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation March 2026 © LeonaBio, Inc.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K/A
December 2025 Corporate Presentation © Athira Pharma, Inc.
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K/A
Risks Related to Our Business and the Development of Our Drug Candidates
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K/A
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
December 2025 Corporate Presentation © Athira Pharma, Inc.
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Risks Related to Our Business and the Development of Our Drug Candidates
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LIFT-AD Topline Readout September 3, 2024 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
Other events · EX-99.1 to Form 8-K
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Athira Pharma Reports First Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase 2/3 LIFT-AD Interim Analysis Results and Next Steps October 17, 2022 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ACT-AD Topline Results Investor Webinar June 22, 2022 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Athira Pharma Reports First Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Athira Pharma Announces Leadership Changes;
Executive or director change · Other events · EX-99.1 to Form 8-K